#CureSMA2021 – Apitegromab Safely Increases Motor Abilities in SMA Types 2, 3

#CureSMA2021 – Apitegromab Safely Increases Motor Abilities in SMA Types 2, 3

296694

#CureSMA2021 – Apitegromab Safely Increases Motor Abilities in SMA Types 2, 3

Meaningful further improvements in motor skills were evident with apitegromab treatment in later-onset spinal muscular atrophy (SMA) patients on maintenance doses of Spinraza (nusinersen), updated Phase 2 TOPAZ trial findings show. “The TOPAZ results show that apitegromab has promising potential to benefit the large portion of individuals with SMA who still manifest muscle weakness,” Thomas Crawford, MD, the trial’s lead investigator, said in a press release. These data were presented by Crawford at the recent 2021 Virtual SMA Research…

You must be logged in to read/download the full post.